

421A
226-01
M.L.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Patent Application of:)
)
Darrell R. Anderson et al.)
) Group Art Unit: Unassigned
Application No. (Unassigned))
) Examiner: Unassigned
Filed: January 12, 2001)
)
For: HUMAN B7.1-SPECIFIC PRIMATIZED)
ANTIBODIES AND TRANSFECTOMAS)
EXPRESSING SAID ANTIBODIES)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, kindly cancel Claims 1-20 (all of the original claims) and insert the following new claims:

--21. A method of treating B cell lymphoma comprising administering a therapeutically effective amount of an anti-B7 antibody.

22. The method of claim 21 wherein said B7 is B7.1 and/or B7.2.

23. The method of claim 21 wherein said B7 is B7.1.

24. The method of claim 21 wherein said anti-B7 antibody binds the same epitope as an anti-B7.1 antibody selected from the group consisting of 16C10, 7C10, 20C9 and 7B6.

Sub D1

A2
comit

Sub D2

25. The method of claim 21 wherein said antibody is a depleting antibody.
26. The method of claim 21 wherein said antibody is a non-depleting antibody.

A2
concl.

27. The method of claim 21 wherein said antibody is a primate antibody.

28. The method of claim 21 wherein said antibody is administered repetitively.

29. The method of claim 21 wherein said antibody is administered parenterally.

30. The method of claim 29 wherein parenterally includes intravenous, intraperitoneal, intramuscular, subcutaneous and rectal administration.

31. The method of claim 21 wherein the antibody comprises human gamma-1 or gamma-4 constant regions.--

Remarks

Entry of the foregoing amendments and favorable consideration on the merits is respectfully requested.

Specific support for these claims may be found at page 32 (line 16), page 30 (lines 11-23) and pages 34-35 of the subject application.